BMRN BioMarin Pharmaceutical Inc.

79.55
-0.05  -0%
Previous Close 79.6
Open 79.06
Price To Book 4.58
Market Cap 14,313,081,639
Shares 179,925,602
Volume 1,329,559
Short Ratio
Av. Daily Volume 1,664,497
Stock charts supplied by TradingView

NewsSee all news

  1. BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe

    SAN RAFAEL, Calif., April 6, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that based on recent meetings with health authorities in the US and Europe, the Company plans to submit

  2. BioMarin's Brinda Balakrishnan, M.D., Ph.D., Honored with 2020 "40 Under 40" Award from the San Francisco Business Times

    SAN RAFAEL, Calif., March 9, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Brinda Balakrishnan, M.D., Ph.D., has been named to the San Francisco Business Times 2020 "40 Under

  3. BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results

    SAN RAFAEL, Calif., Feb. 26, 2020 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended

  4. BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020

    SAN RAFAEL, Calif., Feb. 20, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License

  5. BioMarin to Participate in Two Upcoming Investor Conferences

    SAN RAFAEL, Calif., Feb. 12, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that management will participate in the 9th Annual Leerink Partners Global Healthcare Conference on February

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 52-week data due 1Q 2021.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A
Phase 3 top-line data met primary endpoint - December 16, 2019. Regulatory filing due 3Q 2020.
Vosoritide
Achondroplasia
Approval announced May 24, 2018.
Palynziq (Pegvaliase)
Phenylketonuria (PKU)
Program terminated June 2016
Reveglucosidase alfa (BMN 701)
Pompe Disease
Approved February 14, 2014.
Vimizim (GALNS)
(MPS IVA) Morquio A Syndrome
PDUFA date extended by three months to April 27 2017. Approval announced April 27, 2017.
Cerliponase alfa
Batten Disease
CRL issued January 14, 2016.
Kyndrisa
Duchenne Muscular Dystrophy (DMD)
PDUFA date under priority review August 21, 2020.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A
Phase 1/2 dosing has commenced - noted May 15, 2018.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A with with pre-existing AAV5 antibodies
Phase 1/2 trial to commence 1Q 2020.
BMN 307
Phenylketonuria (PKU)

Latest News

  1. BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe

    SAN RAFAEL, Calif., April 6, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that based on recent meetings with health authorities in the US and Europe, the Company plans to submit

  2. BioMarin's Brinda Balakrishnan, M.D., Ph.D., Honored with 2020 "40 Under 40" Award from the San Francisco Business Times

    SAN RAFAEL, Calif., March 9, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Brinda Balakrishnan, M.D., Ph.D., has been named to the San Francisco Business Times 2020 "40 Under

  3. BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results

    SAN RAFAEL, Calif., Feb. 26, 2020 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended

  4. BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020

    SAN RAFAEL, Calif., Feb. 20, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License

  5. BioMarin to Participate in Two Upcoming Investor Conferences

    SAN RAFAEL, Calif., Feb. 12, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that management will participate in the 9th Annual Leerink Partners Global Healthcare Conference on February

  6. BioMarin Announces CFO Succession

    SAN RAFAEL, Calif., Feb. 3, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced the transition of Executive Vice President and Chief Financial Officer Dan Spiegelman.  Mr. Spiegelman will

  7. BioMarin to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Wednesday, February 26 at 4:30pm ET

    SAN RAFAEL, Calif., Jan. 29, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and

  8. BioMarin, Pioneer in Phenylketonuria, to Begin Clinical Trial with BMN 307 Gene Therapy

    SAN RAFAEL, Calif., Jan. 13, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a pioneer in treatments for the rare disease Phenylketonuria (PKU) and in gene therapy clinical research, announced today that

  9. BioMarin to Participate in Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top on January 9, 2020 in New York

    SAN RAFAEL, Calif., Jan. 8, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at Goldman Sachs 12th Annual

  10. Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy

    SAN FRANCISCO, Jan. 8, 2020 /PRNewswire/ -- Today BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Invitae Corporation (NYSE:NVTA) announced that Biogen (NASDAQ:BIIB), Encoded Therapeutics, Neurogene, Praxis Precision

  11. BioMarin to Present at 38th Annual J.P. Morgan Healthcare Conference in San Francisco

    SAN RAFAEL, Calif., Jan. 6, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 38th Annual J.P.

  12. BioMarin Announces New England Journal of Medicine Publishes 3 Years of Follow-up Data in Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

    SAN RAFAEL, Calif., Jan. 2, 2020 /PRNewswire/ --BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the New England Journal of Medicine (NEJM) published an independently peer-reviewed article on up to three

  13. BioMarin Submits Biologics License Application to U.S. Food and Drug Administration for Valoctocogene Roxaparvovec to Treat Hemophilia A

    SAN RAFAEL, Calif., Dec. 23, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA)

  14. European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A

    SAN RAFAEL, Calif., Dec. 23, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the European Medicines Agency (EMA) validated the Company's Marketing Authorization Application (MAA)

  15. BioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated with Vosoritide

    SAN RAFAEL, Calif., Dec. 16, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today reported positive final results from its randomized, double-blind, placebo-controlled Phase 3 study evaluating the

  16. BioMarin Submits Marketing Authorization Application to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A

    SAN RAFAEL, Calif., Nov. 21, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA)

  17. Poised for Significant Growth and Profitability, BioMarin Shares Company Highlights During R&D Day on November 14th in New York

    SAN RAFAEL, Calif., Nov. 14, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) updated the investment community on the Company's research and development portfolio, which is focused on innovative

  18. BioMarin Announces Cumulative Additional Height Gain of 9.0 cm over 54 months versus Natural History in Children with Achondroplasia Treated with Vosoritide in Phase 2 Study

    SAN RAFAEL, Calif., Nov. 14, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) provided an update on its clinical program for vosoritide, an analog of C-type Natriuretic Peptide (CNP), in children with

  19. BioMarin to Participate in Jefferies London Healthcare Conference on November 21, 2019

    SAN RAFAEL, Calif., Nov. 12, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Jefferies London

  20. BioMarin to Highlight Innovative Development Pipeline at R&D Day on November 14th

    SAN RAFAEL, Calif., Nov. 6, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will host an R&D Day at 8:00am ET on Thursday, November 14, 2019. BioMarin management and external experts will provide an

  21. BioMarin to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, October 23 at 4:30pm ET

    SAN RAFAEL, Calif., Oct. 9, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and

  22. BioMarin Promotes Lon Cardon, Ph.D. to Chief Scientific Strategy Officer

    SAN RAFAEL, Calif., Oct. 7, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the promotion of Lon Cardon, Ph.D. to Chief Scientific Strategy Officer, a newly created role to enrich

  23. BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York

    SAN RAFAEL, Calif., Oct. 1, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Robert Baffi, Ph.D., President of Global Manufacturing and Technical Operations, will participate in a

  24. BioMarin, Pioneer in Phenylketonuria (PKU) Therapies, Submits Clinical Trial Application (CTA) in U.K. for Investigational Gene Therapy for PKU

    SAN RAFAEL, Calif., Sept. 26, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a pioneer in treatments for rare disease Phenylketonuria (PKU) and in gene therapies, today announced that it has submitted a

  25. BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York

    SAN RAFAEL, Calif., Sept. 9, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer and Henry Fuchs, M.D., President,

  26. BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York

    SAN RAFAEL, Calif., Aug. 28, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer, will present at the Morgan Stanley